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Rosacea is a common skin disease with a high impact on quality of life. Characterized by erythema, edema,
burning pain, immune infiltration, and facial skin fibrosis, rosacea has all the characteristics of neurogenic
inflammation, a condition induced by sensory nerves via antidromically released neuromediators. To investigate
the hypothesis of a central role of neural interactions in the pathophysiology, we analyzed molecular and
morphological characteristics in the different subtypes of rosacea by immunohistochemistry, double
immunofluorescence, morphometry, real-time PCR, and gene array analysis, and compared the findings with
those for lupus erythematosus or healthy skin. Our results showed significantly dilated blood and lymphatic
vessels. Signs of angiogenesis were only evident in phymatous rosacea. The number of mast cells and
fibroblasts was increased in rosacea, already in subtypes in which fibrosis is not clinically apparent, indicating
early activation. Sensory nerves were closely associated with blood vessels and mast cells, and were increased
in erythematous rosacea. Gene array studies and qRT-PCR confirmed upregulation of genes involved in
vasoregulation and neurogenic inflammation. Thus, dysregulation of mediators and receptors implicated in
neurovascular and neuroimmune communication may be crucial at early stages of rosacea. Drugs that function
on neurovascular and/or neuroimmune communication may be beneficial for the treatment of rosacea.
Journal of Investigative Dermatology Symposium Proceedings (2011) 15, 53–62; doi:10.1038/jidsymp.2011.6
INTRODUCTION
Rosacea is a common chronic inflammatory skin disease
primarily characterized by transient or persistent facial
erythema, telangiectasia, papules, pustules and/or edema,
and burning pain, possibly resulting in fibrotic, phymatous
rosacea (Marks, 1989; Wilkin et al., 2002; Powell, 2005). As
the etiology and pathogenesis remains uncertain, treatment
mainly targets the symptoms instead of modulating the
pathophysiological process (Crawford et al., 2004).
Four different subtypes have been defined based on typical
clinical characteristics: erythematotelangiectatic rosacea
(ETR), papulopustular rosacea (PPR), phymatous rosacea
(PhR), and ocular rosacea (Wilkin et al., 2002).
Endogenous key factors of this complex pathogenic
interplay—blood vessels, lymphatic vessels, fibroblasts
(FBs), and cells of the immune system—have been identified
(Marks, 1969; Jansen and Plewig, 1997; Aroni et al., 2004;
Crawford et al., 2004; Gomaa et al., 2007). However, the
underlying mechanisms of onset and maintenance of
molecular and cellular alterations, and the connection
between involved cells, are not yet understood (Crawford
et al., 2004).
Several triggers that exacerbate rosacea have been
identified: UV radiation, temperature changes (heat and
cold), chemical irritation, strong emotions, alcoholic bev-
erages, and spicy food (Jansen and Plewig, 1997), and
probably microbial agents (Lacey et al., 2007; Whitfeld et al.,
2011). Rosacea patients appear susceptible to certain banal
stimuli. This modification of cutaneous sensitivity indicates
the relevance of the sensory and/or autonomic nervous
system in the pathogenesis of the disease (Steinhoff et al.,
2011; Guzman-Sanchez et al., 2007). Interestingly, neuro-
genic inflammation, a condition evoked by released neuro-
peptides after stimulation of sensory nerve endings (Cevikbas
et al., 2007), resembles clinical features of rosacea such as
local erythema, edema, hyperemia, and recruitment of
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leukocytes to the site of inflammation. In addition, stimula-
tion of mast cells (MCs) by neuropeptides and consecutive
release of histamine, tryptase, and other mediators mediates
inflammation, as well as itchy and/or burning sensations
(Steinhoff et al., 2000; Arck et al., 2006; Ikoma et al., 2006).
With respect to sensory and autonomic nerves in this
disease, one problem is that the RNA is harbored in ganglia
and is therefore not detectable by skin biopsies. Another
limiting factor is that the local concentration of released
neuromediators is often under the detection limit of protein
assays or immunohistochemistry. Therefore, little investiga-
tion in this aspect of rosacea has been made until now. For a
comprehensive approach, we analyzed the neurovascular
and neuroimmune alterations at different clinical stages of
rosacea, both on the RNA and protein level by quantitative
real-time RT-PCR (qRT-PCR), and by immunohistochemistry
using markers for nerves, blood vessel, endothelial cells,
lymphatic vessels, FBs, and MCs.
RESULTS
Anatomical association of sensory nerves, MCs, and blood
vessels in rosacea
To determine the anatomical association of facial unmyeli-
nated sensory nerves with the vascular and immune system
(MCs) in rosacea, we performed double immunofluorescence
(IF, Figure 1). A close colocalization was observed between
PGP9.5-positive sensory nerves and blood vessels, as well as
MCs. Some myofibroblasts were colocalized with free nerve
endings. Lymphatic vessels were rarely colocalized with
unmyelinated nerves.
Marked vasodilatation, not angiogenesis, in rosacea
The aim of this study was to quantify vessel number and
circumference in rosacea. Staining with CD31, a marker for
blood vessel endothelium, showed grossly dilated vessels in
all subtypes of rosacea (Figure 2a–h). Morphometrical
analysis demonstrated statistically significant enhancement
of CD31-positive tissue in ETR (Po0.01) and PhR (Po0.05),
as well as perimeter enlargement (Po0.05). The number of
vessels was not increased significantly when compared with
healthy skin (HS). Accordingly, gene array studies combined
with qRT-PCR revealed no upregulation of angiogenic
key genes in ETR and PPR and only slight changes in PhR
(Figure 6a).
Dilatation of lymphatic vessels, not lymphangiogenesis, in
rosacea
The task was to determine the number and circumference of
lymphatic vessels in rosacea. Staining with podoplanin, a
marker for lymphatic vessels, showed vasodilation in all
subtypes (Figure 2i–p). Morphometric analysis showed a
statistically significant augmentation in vessel surface
(Po0.01) and perimeter (Po0.05) exclusively in ETR. The
number of vessels was not altered significantly in any subtype
of rosacea. Investigation of lymphangiogenic key genes by
gene array analysis and qRT-PCR revealed upregulation of
podoplanin in all subtypes, whereas LYVE1 was down-
regulated and VEGFC or PROX1 were unchanged when
compared with HS (Figure 6b).
Slightly enhanced number of myelinated nerve fibers in
subtypes of rosacea
We next sought to address the question of whether
myelinated (neurofilament-positive, NF-200) and/or unmye-
linated (PGP9.5-positive) nerve fibers are anatomically
closely associated with other skin structures in rosacea skin
in comparison with lupus erythematosus (LE) and HS
(Figure 3). Unfortunately, PGP staining is hard to interpret
by light microscopy because of the thin, irregular positive
staining under these conditions. Here, IF is the better
technique. Therefore, we first determined whether myeli-
nated nerves, which are ultimately involved in pain
transmission, are found in increased numbers in rosacea
patients. Double IF results for unmyelinated nerves (PGP9.5)
were analyzed qualitatively and showed close anatomic
association (Figure 1a–d, other data not shown). Staining with
NF-200 showed a higher density of neural structures,
especially in the upper dermis (Figure 3). Morphometrical
analysis demonstrated an increase of nerves, especially in
ETR, but not PPR and PhR. Although clear differences in
nerve numbers were observed between rosacea subtypes and
HS, the data did not reach statistical significance.
Our analysis of expression levels of genes involved in
neurovascular and neuroimmune interactions revealed upre-
gulation in pituitary adenylate cyclase-activating polypeptide
(PACAP), vasoactive intestinal peptide (VIP), HTR3A
(5-hydroxytryptamine (serotonin) receptor 3A), nerve growth
factor beta, adrenergic, alpha-1D-, receptor (ADRA1D),
adrenomedullin 2, and cathelicidin antimicrobial peptide
CD31 Pod
SMATry
Figure 1. Association of different vascular and immune structures with
sensory nerves in human facial skin of rosacea patients, as shown by double
immunofluorescence staining. Colocalization of sensory nerves (PGP9.5)
was determined in combination with CD31 for blood vessels (a), podoplanin
(Pod) for lymphatic vessels (b), tryptase (Try) for mast cells (c), and smooth
muscle actin (SMA) for myofibroblasts or blood vessels (d). Our data show a
close anatomical association of unmyelinated nerves, especially with blood
vessels and mast cells, and less with lymphatic vessels or myofibroblasts
(bar¼ 300 mm; a–c and bar¼ 100mm; d).
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Figure 2. Density of blood and lymphatic vessels in human skin, as shown by immunohistochemistry and quantitative analysis of stained dermis.
Immunoreactivity for CD31 and podoplanin was observed in erythematous rosacea (ETR, n¼ 9), papulopustular rosacea (PPR, n¼9), phymatous rosacea (PhR,
n¼ 9), lupus erythematosus (LE, n¼ 9), and healthy skin staining (HS, n¼10; bar¼100 mm; a–e and i–m). (f) PhR showed strongest statistically significant
augmentation of CD31-positive tissue, followed by ETR (f–h; n–p; *Po0.05; **Po0.01). (g) Vessel perimeter measurement showed significant vasodilation in
ETR and PhR, whereas the number of vessels (h) was not increased. A tendency toward angiogenesis was only observed in PhR. Augmentation in lymph vessel
surface was statistically significant exclusively in ETR (n). Lymph vessel circumference measurements showed significant vasodilation in ETR (o). Number of
lymphatic vessels was not increased in any subtype (p), unfilled triangles and circles represent outliers (f–h; n–p).
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(Figure 6c). Downregulation was detected in VIP receptor-1,
PACAP receptor-1, nerve growth factor receptor (trkA),
kallikrein-related peptidase-5, diverse adrenergic receptors
(ADRB2/3, ADRA2C/1B), neuropeptide Y, and tachykinin,
precursor 1/substance P.
Increased MC numbers in all subtypes of rosacea
MCs are functionally closely associated with both blood
vessels and nerves, and altogether form a so-called micro-
vascular unit (Steinhoff et al., 2003). We sought to determine
the number of MCs in the various subtypes of rosacea, and to
analyze the potential increase of MC associated with vascular
structures, nerves, and FBs (Figure 4).
Quantitative analysis of tryptase staining revealed a
statistically significant increased density of MC in all subtypes
of rosacea, especially in PPR (Po0.05) followed by ETR
(Po0.01) and PhR (Po0.05).
To analyze the genes associated with MC function, we
investigated the mRNA expression levels of histamine
receptors (HRH1–4; Figure 6d). Our gene array data showed
upregulation of HRH2 and HRH3. Gene expression of HRH1
was not altered, and HRH4 was downregulated.
Increased staining of Vimentin-positive cells in rosacea
Fibrocytes/blasts have an essential role in the induction of
skin fibrosis. Quantitative analysis of vimentin staining, a
marker for fibrocytes/blasts and mesenchymal structures of
blood vessels, demonstrated a statistically significant higher
density of FB in PPR (Po0.01), followed by ETR (Po0.05) as
compared with controls (Figure 5). Accordingly, qRT-PCR
showed strong upregulation of genes involved in matrix
remodeling as well, especially in PPR and PhR. Upregulation
of matrix metalloproteinase (MMP)-1 and -12 was strongest,
followed by upregulation of MMP-10, -3, and -9. All MMP
inhibitors were downregulated at the RNA level (Figure 6e).
DISCUSSION
The involvement of neuroimmune and neurovascular com-
munication in the pathophysiology of rosacea is currently
indicated only by clinical observation. Therefore, we
examined the morphological and molecular correlation of
various cells involved in the pathophysiology of rosacea and
their specific pattern in the various subtypes of rosacea as
compared with LE and HS. Our results show a close anatomic
association of sensory nerves, blood vessels, and immune
cells, as well as signs of neuroimmune and neurovascular
communication such as vasodilation, rather than angiogen-
esis, dilated lymphatic vessels, and a strong increase in MC
and FB numbers. In accordance with that finding, our qRT-
PCR data demonstrate upregulation of receptors that are
targets for mediators released by MC or sensory nerve endings.
Taken together, our results strongly suggest substantial
neurovascular and neuroimmune interaction in the pathophy-
siology of rosacea. In comparison with rosacea, LE also
showed increased vasodilatation of blood vessels and lym-
phatic vessels, but no increase in nerves, MC, or FB numbers.
Our findings of significant vasodilatation in all subtypes of
rosacea correlate well with symptoms such as flushing and
erythema. Some authors proclaimed that angiogenesis has an
important role in the pathogenesis, and suggested that the
increase in vascular tissue, in particular, was due to this
(Aroni et al., 2008; Gomaa et al., 2007). Morphologically, we
could not find an increase in the vessel number in any
subtype, whereas significant vasodilation was obvious. This
finding correlates well with our gene array and qRT-PCR
data, in which expression of angiogenic key genes was rarely
modulated. PhR showed slight upregulation as well as
downregulation of angiogenic genes as a sign of increased
tissue remodeling.
The mechanism(s) that induce rapid flushing and erythema
in rosacea are still unknown (Sobottka and Lehmann, 2009).
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Figure 3. Localization and density of myelinated sensory nerves (NF200) in human skin, as shown by immunohistochemistry and quantitative analysis of
stained dermis. Immunoreactivity for neurofilament was observed in erythematous rosacea (ETR, n¼ 9), papulopustular rosacea (PPR; n¼ 9), phymatous rosacea
(PhR; n¼ 9), lupus erythematosus (LE; n¼ 9), and healthy skin (HS; n¼ 10; bar¼ 100mm; a–e). There was a marked but not statistically significant increase of
nerves in ETR ( 2.34) followed by a gradual decrease. Increase of neurofilament-positive nerves was comparable in PPR and LE (unfilled circle represents
outlier) (f).
56 Journal of Investigative Dermatology Symposium Proceedings (2011), Volume 15
VD Schwab et al.
Pathophysiology of Rosacea
Despite the prominent telangiectasia, blood vessels maintain
their ability to respond to vasoactive stimuli (Guarrera et al.,
1982), suggesting that changes are not structural or due to
irreversible damage. However, our molecular investigation
indicates a marked upregulation of genes that are involved in
vasodilatation. Thus, sensory nerves may induce vasodilata-
tion by activating high-affinity receptors for vasoregulatory
neuropeptides on endothelial cells and/or smooth muscle
cells surrounding vessels. In LE, lymphatic vessels were
extremely dilated, whereas rapid flushing such as in rosacea
is rarely observed in LE. This may explain the differences with
respect to the strong neurovascular association in early
rosacea but not in later subtypes and LE.
Recently, the lymphatic system has attracted growing
interest as an important contributor during chronic inflam-
mation (Huggenberger et al., 2010). Our results suggest that
lymphatic vessels are already involved in the initiation
process of rosacea but not in later subtypes, although
clinically visible signs of edema are described at later stages
(Crawford et al., 2004). Although the early involvement of
lymphatic tissue was suggested before, augmentation of
lymphatic tissue was previously attributed mainly to lym-
phangiogenesis (Gomaa et al., 2007). Our morphometric
results show no enhancement in vessel number when
compared with HS. Furthermore, our RT-PCR results showed
that most of the genes involved in growth and elongation of
ETR
ETR
PPR
PPR
PhR
PhR
HS
HS
LE
LE
0
1
2
*
*
*
**3
4
5
6
Ef
fe
ct
ive
 p
os
itiv
e 
ar
ea
Figure 4. Localization and density of mast cells in human facial skin as shown by immunohistochemistry and quantitative analysis of stained dermis.
Immunoreactivity for tryptase was observed in erythematous rosacea (ETR, n¼ 9), papulopustular rosacea (PPR, n¼9), phymatous rosacea (PhR, n¼9),
lupus erythematosus (LE; n¼ 9), and healthy skin (HS, n¼ 10; bar¼100 mm; a–e). The increase in mast cell density was statistically significant for all subtypes
(ETR  3.98; PPR 4.41; PhR  2.54), whereas mast cell density did not increase in LE (*Po0.05, **Po0.01; unfilled circles and triangle represent outliers) (f).
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Figure 5. Localization and density of fibroblasts (FBs)/cytes and mesenchymal structures of blood vessels in human skin, as shown by immunohistochemistry
and quantitative analysis of stained dermis. Immunoreactivity for vimentin was observed in erythematous rosacea (ETR, n¼9), papulopustular rosacea
(PPR, n¼ 9), phymatous rosacea (PhR, n¼ 9), lupus erythematosus (LE; n¼9), and healthy skin (HS; n¼ 10; bar¼ 100mm; a–e). Density of FBs was increased in
all subtypes, but significantly so in ETR ( 2.9) and PPR (3.94). Skin of lupus patients showed decreased density of FBs/cytes as compared with healthy human
skin (*Po0.05; **Po0.01; unfilled circle represents outlier) (f).
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Angiogenesis ETR PPR PhR Long term of gene Reference
CD79A 1.82 2.66 11.04 CD79a molecule, immunoglobulin-associated alpha Hs00998119_m1
FLT1 3.32 2.46 5.70 Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor recepto 1m_63925010sH)r
CDH2 5.80 4.78 3.55 Cadherin 2, type 1, N-cadherin (neuronal) Hs00983062_m1
CD68 1.54 2.27 3.29 CD68 molecule Hs00154355_m1
FGF1 2.38 1.55 3.01 Fibroblast growth factor 1 (acidic) Hs00361126_m1
ANGPT2 1.71 2.10 2.92 Angiopoietin 2 Hs01048043_m1
TIMP4 2.82 1.64 2.91 TIMP metallopeptidase inhibitor 4 Hs00162784_m1
IL13RA1 1.90 1.62 2.58 Interleukin 13 receptor, alpha 1 Hs00609817_m1
PGF 1.70 2.56 2.05 Placental growth factor, vascular endothelial growth factor-related protein Hs01119262_m1
ENG 1.30 1.69 1.97 Endoglin (Osler-Rendu-Weber syndrome 1) Hs00164438_m1
EDNRA 1.27 1.10 1.82 Endothelin receptor type A Hs00609865_m1
EDN3 0.88 1.41 1.79 Endothelin 3 Hs00171177_m1
KDR 1.33 1.71 1.77 Kinase insert domain receptor (a type III receptor tyrosine kinase) Hs00176676_m1
VEGFA 1.51 1.63 1.61 Vascular endothelial growth factor A Hs00900054_m1
PECAM1 1.19 1.47 1.61 Platelet/endothelial cell adhesion molecule (CD31 antigen) Hs00169777_m1
PPARD 1.16 1.34 1.56 Peroxisome proliferator-activated receptor delta Hs00602622_m1
HGF 0.98 0.86 1.45 Hepatocyte growth factor (hepapoietin A; scatter factor) Hs00300159_m1
THBS1 1.25 1.62 1.42 Thrombospondin 1 Hs00962914_m1
HIF1A 1.00 1.32 1.28 Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Hs00936368_m1
CDH1 1.19 1.23 1.27 Cadherin 1, type 1, E-cadherin (epithelial) Hs00170423_m1
ECE1 1.00 1.30 1.18 Endothelin converting enzyme 1 Hs01043735_m1
TEK 0.91 1.07 1.14 TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal = TIE2) Hs00176096_m1
CD44 1.04 1.37 1.03 CD44 molecule (Indian blood group) Hs00153310_m1
EDNRB 0.93 1.16 0.95 Endothelin receptor type B Hs00240747_m1
THBS2 0.75 0.83 0.95 Thrombospondin 2 Hs00170248_m1
COL18A1 0.64 0.82 0.82 Collagen, type XVIII, alpha 1 Hs00181017_m1
TIMP1 0.82 0.99 0.77 TIMP metallopeptidase inhibitor 1 Hs00171558_m1
ANGPT4 0.61 0.74 0.70 Angiopoietin 4 Hs00211115_m1
ECE2 0.61 0.74 0.70 Endothelin converting enzyme 2 Hs00206701_m1
VEGFB 0.67 0.65 0.68 Vascular endothelial growth factor B Hs00173634_m1
IL13RA2 1.22 1.80 0.66 Interleukin 13 receptor, alpha 2 Hs00152924_m1
EDN2 1.12 1.13 0.66 Endothelin 2 Hs01012714_m1
ANGPT1 0.58 0.41 0.66 Angiopoietin 1 Hs00375823_m1
FGFR1 0.78 0.66 0.66 Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) Hs00241111_m1
FGF2 0.96 1.09 0.63 Fibroblast growth factor 2 (basic) Hs00266645_m1
CD1A 0.60 0.57 0.60 CD1a molecule Hs00233332_m1
CD34 0.56 0.62 0.57 CD34 molecule Hs00156373_m1
FGFR2 0.61 0.74 0.49 Fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor rec., craniofacial dysostosis 1) Hs00240792_m1
EDN1 0.52 0.56 0.44 Endothelin 1 Hs00174961_m1
GPR39 0.38 0.30 0.39 G-protein-coupled receptor 39 Hs00230762_m1
ANG 0.57 0.48 0.41 Angiogenin, ribonuclease, RNase A family, 5 Hs02379000_s1
NCAM1 1.49 1.16 0.38 Neural cell adhesion molecule 1 Hs00169851_m1
TIMP2 0.40 0.41 0.37 TIMP metallopeptidase inhibitor 2 Hs00234278_m1
ELA2 0.98 0.62 0.34 Elastase 2, neutrophil Hs00236952_m1
b Lymphangiogenesis
PDPN 3.11 3.52 3.39 Podoplanin Hs00366764_m1
VEGFC 1.02 0.98 1.37 Vascular endothelial growth factor C Hs00153458_m1
PROX1 0.90 0.86 0.62 Prospero homeobox 1 Hs00160463_m1
LYVE1 0.24 0.18 0.14 Lymphatic vessel endothelial hyaluronan receptor 1 Hs00272659_m1
c Neuro-inflammation
TRPA1 13.60 8.54 33.44 Transient receptor potential cation channel, subfamily A, member 1 Hs00175798_m1
ADCYAP1 21.29 16.78 23.12 Adenylate cyclase activating polypeptide 1 (pituitary) Hs00174950_m1
HTR3A 1.04 4.76 13.31 5-Hydroxytryptamine (serotonin) receptor 3A Hs00168375_m1
CAMP 7.46 7.03 12.61 Cathelicidin antimicrobial peptide Hs00189038_m1
ADM2 4.82 8.23 7.49 Adrenomedullin 2 Hs00363866_m1
VIP 7.66 7.43 5.79 Vasoactive intestinal peptide Hs00175021_m1
ADRA1D 3.67 1.38 2.91 Adrenergic, alpha-1D-, receptor Hs00169865_m1
CALCR 1.36 1.59 1.98 Calcitonin receptor Hs01016882_m1
ADRB1 2.01 1.37 1.75 Adrenergic, beta-1-, receptor Hs02330048_s1
CALCRL 1.08 1.25 1.62 calcitonin receptor-like Hs00173787_m1
NGFB 2.26 1.57 1.35 Nerve growth factor, beta polypeptide Hs00171458_m1
KLK5 0.59 0.46 1.22 Kallikrein-related peptidase 5 (Synonyms=SCTE) Hs00202752_m1
ADRA2A 0.86 1.03 1.20 Adrenergic, alpha-2A-, receptor Hs00265081_s1
HTR2A 0.64 1.72 1.17 5-Hydroxytryptamine (serotonin) receptor 2A Hs00167241_m1
ADM 1.02 0.89 0.97 Adrenomedullin Hs00181605_m1
ADCYAP1R1 1.41 1.06 0.76 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I Hs00153869_m1
CALCA 0.61 0.83 0.70 Calcitonin/calcitonin-related polypeptide, alpha Hs00266142_m1
TRPV5 0.61 0.83 0.70 Transient receptor potential cation channel, subfamily V, member 5 Hs00219765_m1
ADRA2C 1.37 1.03 0.66 Adrenergic, alpha-2C-, receptor Hs01896125_s1
ADRA2B 0.85 0.92 0.64 Adrenergic, alpha-2B-, receptor Hs00265090_s1
VIPR1 0.59 0.64 0.56 Vasoactive intestinal peptide receptor 1 Hs00270351_m1
NGFR 1.11 1.13 0.56 Nerve growth factor receptor (TNFR superfamily, member 16) Hs00182120_m1
MMEL1 1.21 0.79 0.36 Neprilysin Hs00364353_m1
ADRB3 0.39 0.68 0.32 Adrenergic, beta-3-, receptor Hs00609046_m1
TRPV6 0.41 0.33 0.31 Transient receptor potential cation channel, subfamily V, member 6 Hs00367960_m1
VIPR2 0.78 1.51 0.29 Vasoactive intestinal peptide receptor 2 Hs00173643_m1
ADRB2 0.29 0.40 0.25 Adrenergic, beta-2-, receptor, surface Hs00240532_s1
NPY 1.34 1.04 0.21 Neuropeptide Y Hs00173470_m1
DRD1 1.11 0.39 0.20 Dopamine receptor D1 Hs00265245_s1
ADRA1B 0.36 0.17 0.14 Adrenergic, alpha-1B-, receptor Hs00171263_m1
ADRA1A 0.58 0.53 0.02 Adrenergic, alpha-1A-, receptor Hs00169124_m1
TAC1 0.11 0.20 0.02 Tachykinin, precursor 1 (substance K, substance P, neurokinin 1/ 2, neuromedin L, neurokinin alpha, neuropeptide K/ gamma) Hs00243227_m1
d Histamin receptors
HRH3 6.45 13.03 10.12 Histamine receptor H3 Hs00200610_m1
HRH2 2.73 9.01 4.69 Histamine receptor H2 Hs00254569_s1
HRH1 1.11 1.42 0.55 Histamine receptor H1 Hs00185542_m1
HRH4 0.44 1.02 0.61 Histamine receptor H4 Hs00222094_m1
e  Tissue remodeling
MMP12 39.9             118.3         75.6           Matrix metallopeptidase 12 (macrophage elastase) Hs00899668_m1
MMP1 20.3             94.0           212.5         Matrix metallopeptidase 1 (interstitial collagenase) Hs00233958_m1
MMP10 4.5               15.1           7.6             Matrix metallopeptidase 10 (stromelysin 2) Hs00233987_m1
MMP3 5.6               14.8           17.9           Matrix metallopeptidase 3 (stromelysin 1, progelatinase) Hs00968308_m1
MMP9 4.6               7.0             11.7           Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) Hs00234579_m1
MMP2 0.5               0.7             0.9             Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) Hs00234422_m1
MMP8 0.7               0.6             3.5             Matrix metallopeptidase 8 (neutrophil collagenase) Hs00233972_m1
TIMP4 2.8               1.6             2.9             TIMP metallopeptidase inhibitor 4 Hs00162784_m1
TIMP1 0.8               1.0             0.8             TIMP metallopeptidase inhibitor 1 Hs00171558_m1
TIMP3 0.6               0.5             0.3             TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) Hs00165949_m1
TIMP2 0.4             0.4           0.4            TIMP metallopeptidase inhibitor 2 Hs00234278_m1
Mean fold induction
a 
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lymphatic capillaries were only slightly or not at all
upregulated. LYVE1, a gene having a key role in metabolism,
binding, and transport of hyaluronic acid from tissues to
lymphatic vessels and in transplacement of leukocytes in
lymphatic vessels and lymph nodes (Jackson, 2009), was
even downregulated (Figure 6b).
Little data exist about a possible influence of the nervous
system on lymph vascular tissue. Some studies showed that
neuropeptides affect the function of lymphatic vessels. For
example, substance P induces the reduction in diastolic and
systolic vessel diameter, stroke volume, and increase in
contraction frequency (Amerini et al., 2004), and calcitonin
gene-related peptide dose dependently inhibits the vasomo-
tion of lymph vessels (Hosaka et al., 2006). Which of the
neuropeptides involved in rosacea pathophysiology affect
lymphatic function has to be clarified in detailed studies.
A recent theory that received greater emphasis in the
pathophysiology of rosacea suggests the involvement of
mechanisms of neurogenic inflammation, which may reflect
the early and late clinical features of the disease including
flushing, erythema, and induction of leukocyte infiltration,
especially of MCs (Steinhoff et al., 2003; Roosterman et al.,
2006; Reich et al., 2010). Although statistically not signifi-
cant, we found a clear tendency of increased nerve density,
especially in ETR, followed by a decrease in PhR. Reflecting
those morphometrical findings, sensations such as ‘‘pricking,
burning, or pain’’ are predominantly known in ETR and PPR,
followed by less sensation in PhR (Crawford et al., 2004;
Sobottka and Lehmann, 2009).
To further investigate the role of sensory nerves in the
context of intercellular communication, we performed double
IF staining, which showed a close anatomical association of
sensory nerves, especially with blood vessels and MCs.
Pathways of neurovascular and neuroimmune interactions in
the pathophysiology of rosacea are still unknown; therefore,
we analyzed gene expression levels of neuromediators and
neuroreceptors at the RNA level. Note that these genes must
be expressed by non-neuronal cells, because the neuronal
genes are located in the dorsal root ganglia.
So far, suggested communicating neuropeptides involved
in rosacea include calcitonin gene-related peptide and
substance P (tachykinin, precursor 1; Powell et al., 1993;
Lonne-Rahm et al., 2004). Unexpectedly, neither of these
neuropeptides nor their receptors was upregulated at the
RNA level, but were rather downregulated (Figure 6c).
According to our results, their relevance in rosacea is rather
marginal. In contrast, we recognized some new molecular
pathways, which we do not believe to have been linked to
the pathophysiology of rosacea until now.
Gene analysis showed upregulation of serotonin receptor
HTR3A. Serotonin (5-hydroxytryptamine) is an important
inflammatory and neurosensory mediator that is released
from platelets and MCs, thereby contributing to nociception
and vasoregulation (Oliveira et al., 2007). Expressed by
primary afferent nerve fibers, HTR3A conveys their excitation
and sensitization. 5-Hydroxytryptamine and the responding
receptors have already been investigated for other inflamma-
tory skin diseases (Nordlind et al., 2006), but, to our
knowledge, contribution of 5-hydroxytryptamine in the
pathophysiology of rosacea has not been studied. It has been
reported that HTR3A antagonist Ondansetron led to good
remissions of cutaneous symptoms in rosacea patients
(Wollina, 1999). Thus, HTR3A antagonization may be a
promising future therapeutic approach.
Cathelicidin antimicrobial peptide, a recently described
antimicrobial peptide, was upregulated in all subtypes.
Processed by kallikrein-5, cathelicidin antimicrobial peptide
has proinflammatory activity, and promotes angiogenesis and
chemotaxis. Yamasaki et al, (2007, 2011) suggest cathelicidin
antimicrobial peptide to be one factor eliciting an exacer-
bated response of the innate immune system (Morizane
et al., 2010).
Moreover, our molecular studies demonstrated that
vasoactive neuropeptides such as PACAP, VIP, or adreno-
medullin (ADR2) were significantly enhanced. PACAP has
already been linked to the pathophysiology of psoriasis
and atopic dermatitis, where it may mediate vasodilatation
and plasma extravasation, and influence neurogenic
inflammation via activation of VPAC receptors (Steinhoff
et al., 1999; Seeliger et al., 2010). Both PACAP and VIP
are capable of stimulating MC degranulation (Peters et al.,
2006; Lenti et al., 2009). Upon stimulation, neuromediators
such as PACAP can also be released by endothelial
cells under inflammatory conditions, suggesting an important
role of PACAP, VIP, or transient receptor potential
channels, as well as adrenergic receptors, in rosacea
pathophysiology.
MCs have long been known to be key effector cells in
neurogenic inflammation, immune defense, and fibrosis
(Metz and Maurer, 2007). A recent study discussed the
important role of MCs in rosacea’s evolution to a chronic
stage (Aroni et al., 2008).
Our results clearly indicate a marked upregulation of
MC density in all subtypes of rosacea, with the greatest
increase in PPR. In LE, MCs were not significantly increased
compared with MCs in HS, which indicates that the high
density of MCs in rosacea is more than a sign of skin
inflammation in general.
Figure 6. Detection of mRNA levels of genes relevant for neuroimmune and neurovascular interaction as determined by RT-PCR. (a) Fold induction of genes
involved in angiogenesis. Modulation of expression was detectable in phymatous rosacea (PhR, n¼ 6), but not in erythematous rosacea (ETR, n¼11) and
papulopustular rosacea (PPR, n¼11). (b) Fold induction of genes involved in lymphangiogenesis. RT-PCR showed upregulation of podoplanin, but
downregulation of LYVE1. (c) Fold induction of genes involved in neurovascular interaction. RT-PCR showed marked modulation of gene expression of different
neuropeptides and their corresponding receptors in all subtypes. (d) Fold induction of histamine receptors. HRH3 was upregulated. (e) Fold induction of genes
involved in tissue remodeling. RT-PCR shows evidence of a strong enhancement of matrix metalloproteinases (MMPs), whereas their inhibitors are
downregulated.
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Being activated by neuropeptides such as PACAP or VIP,
MCs could be important interconnecters amplifying the
neural impulses and conveying them via histamine or
tryptase release to vasculature and immune cells (Steinhoff
et al., 2003). Our morphometric and gene analysis data,
however, indicate a strong interaction between nerves and
MCs. HRH2, a receptor that mediates vasodilatory effects of
histamine, was upregulated in rosacea, especially in PhR,
when, according to our immunohistochemical findings,
vasodilatation is most impressive. In addition, we observed
a positive correlation between the increase of MCs and FBs in
dermal structures of rosacea tissues, suggesting a strong
interaction, e.g., by MC tryptase, which is known to have a
chemotactic and mitotic effect on FBs (Gruber, 2003). Recent
studies show that MC/FB communication appears to be
involved in skin fibrosis (Monument et al., 2010).
Skin fibrosis and phymatous changes are characteristics of
late-stage rosacea. In our study, we observed a significantly
higher distribution of vimentin-positive cells in rosacea
patients, with a maximum in PPR patients. This finding is
consistent with clinical symptoms such as phymatic changes
and previous histological findings (Jansen and Plewig, 1997).
Activation of FB seems to be a specific feature in rosacea, as
number of FBs is significantly different from that found in LE.
Clinically, the skin in ETR is described to be fine in texture
without obvious signs of fibrosis and fibrotic chances occur
particularly in PhR (Crawford et al., 2004). Unexpectedly,
however, according to our data FB occurrence in skin is vice
versa predominantly in ETR and PPR. This observation leads
us to conclude that fibrotic processes in rosacea start much
earlier than is expected on the basis of clinical observations.
Our qRT-PCR experiments showed massive upregulation
of MMP, especially in PPR and PhR, indicating that a strong
process of remodeling is taking place. MMP inhibitors were
found rather downregulated (Figure 6e). In addition to their
involvement in tissue destruction and fibrosis, MMPs have
recently been found to be involved in angiogenesis and
apoptosis (Ama˘linei et al., 2010). In rosacea, MMP-9 and -2
are known to be involved in the development of neuropathic
pain (Kawasaki et al., 2008) and fibrotic processes. Taken
together, morphometrical and molecular results, effective
inhibition of MMP, e.g., by tetracyclines (Gu et al., 2010;
Lipowsky et al., 2011), may provide a novel therapeutic
approach for the treatment of fibrosis and pain (stinging and
burning) associated with rosacea. The unexpected early
detection of FB activation is very important with respect to
timing rosacea treatment. Here, detailed studies using various
markers of the different FB differentiation stages are necessary
to further dissect the role of FB activation.
In summary, our combined morphological and molecular
study indicates a meaningful role of neurovascular and
neuroimmune networks in the development of rosacea. We
demonstrated, both at the histological and molecular levels,
that neurogenic inflammation is an important part of the
pathophysiology, resulting in vasodilation, but not in
angiogenesis, and contributes to the fibrotic processes
observed in this chronic inflammatory disease. Furthermore,
our study detected some promising pathways of conduction,
which remain to be clarified and validated in detailed studies.
To gradually get to know the different involved parameters
and interaction pathways opens a wide range of new and
finally cause-related pharmacological targets for therapeutic
intervention.
MATERIALS AND METHODS
For detailed descriptions see Supplementary Material online. The
antibodies used are listed in Supplementary Material S1 online. The
ready-to-use TaqMan Gene Expression Assays (Applied Biosystems,
Foster City, CA) are listed in Figure 6.
Skin collection
All facial skin material was obtained from previously taken
diagnostic biopsies (Rosacea, Lupus) and plastic surgery (HS) in
the Department of Dermatology, University Hospital Mu¨nster,
Germany. The clinical diagnosis of rosacea subtypes was performed
according to the classification system of the National Rosacea
Society (Wilkin et al., 2002). On the basis of that, we investigated
five different groups of patients: for morphometric stainings ETR
(n¼ 9), PPR (n¼ 9), PhR (n¼ 9), HS (n¼ 10), LE (n¼ 9); and for gene
analytic studies we investigated the following groups: ETR (n¼ 11),
PPR (n¼ 11), PhR (n¼ 6), HS (n¼ 12, face). Patients were informed
about the possible use of tissue leftover from surgery for investiga-
tion, and gave their written consent. Permission for human studies
was given by the Ethical Committee of the University of Mu¨nster
Germany, in accordance with the ethical standards of the 1964
Declaration of Helsinki Principles.
Double immunofluorescence
Histological staining with double IF was completed according to the
standard protocol (Collins et al., 2002). Frozen sections of skin
samples were processed for double IF staining. Blocking was
performed with Target Retrieval Buffer, pH 6.1 (S1699, DAKO,
Hamburg, Germany) at 90 1C for 40 minutes. Antibody pools were
incubated overnight at 4 1C. After secondary antibodies (1:400) were
washed, they were applied for 60 minutes at room temperature.
Immunohistochemical analysis
Immunohistochemistry was performed as described (Rattenholl
et al., 2007). Paraffin sections of skin samples were deparaffinized
and processed for immunohistochemical staining. Blocking was
performed according to the specific characteristics of the different
markers. Antibody pools were incubated for 1 hour. After secondary
antibodies were washed, they were applied for 30 minutes at room
temperature.
Image analysis
Using  200 magnification, we took five pictures within each
section, moving from epidermis to dermis. The positive stained area
of the dermis was analyzed quantitatively by using specific image
analysis software (Cell D 2.6 (Build 1200), Olympus Soft Imaging
Solutions GmbH; Mu¨nster, Germany).
Quantitative RT-PCR
qRT-PCR was performed as previously described (Sta¨nder et al.,
2004). In short, mRNA expression was evaluated using semiquanti-
tative PCR technology (qRT-PCR–Taqman Low Density Arrays). After
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extraction of total RNA, cDNA was synthesized using high-capacity
cDNA archive kits (Applied Biosystems). Gene expression analysis
was performed using TLDA arrays containing PCR primers for genes
of interest and housekeeping genes. Synthesized cDNA (50 ng of
cDNA per column) was added to the PCR master mix, and PCR
reactions were performed on ABI 7900HT (Applied Biosystems).
Statistical analysis
Statistical analyses for morphometry were performed using SPSS for
Windows, version 17.0 (SPSS, Chicago, IL). Statistical significance
was determined by using t-tests. Differences were considered
significant at a P-value p0.05.
The fold modulation of gene expression of rosacea sam-
ples versus samples of healthy volunteers was defined as
2(meanCtHVmeanCtRo), with CtHV and CtRo depicting the Ct values of
healthy volunteer and rosacea samples, respectively.
To identify gene modulation between rosacea subtypes, one-way
analysis of variance with Benjamini–Hochberg multiplicity correc-
tion was performed using JMP 7.0.1 (SAS Institute, Cary, NC) and
irMF 3.5 (National Institute of Statistical Sciences, NISS, Triangle
Park, NC) software.
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